Overall, the study findings suggest that a $35 cap on insulin OOPCmay help to reduce the risk non‐adherence to insulin for many patients, and that a lower cap may be beneficial in those with T2D and who may be more price sensitive to insulin given that they may have non‐insulin treatment options. The gene discussed is INS; the disease is type 2 diabetes mellitus.